Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109638 | 0.91 | L3MBTL1 (0.57) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL3581480 | 0.88 | KDM4E (0.54) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL26784521 | 0.88 | KDM4E (0.54) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL4874531 | 0.86 | KDM4E (0.60) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL3925783 | 0.86 | KDM4E (0.52) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL3327581 | 0.86 | KDM4E (0.52) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL4740375 | 0.85 | KDM4E (0.51) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL3227432 | 0.85 | KDM4E (0.71) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL4737822 | 0.83 | KDM4E (0.49) | KDM4EHSD17B10L3MBTL1GAAALDH1A1 | |
| SCHEMBL609694 | 0.82 | CASP1 (0.43) | KDM4EALDH1A1MAPTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111303146-A | 3-cyanopyridine compound, pharmaceutical composition containing same, preparation method and application thereof | 中国科学院上海药物研究所 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020119590-A1 | 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. | 中国科学院上海药物研究所 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020119590-A1 | 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. | 中国科学院上海药物研究所 | 2020-06-18 | — | — | WO | disclosed |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | KDM4E 3186/4885HSD17B10 3540/4885L3MBTL1 4856/4885 |
| US-20080039437-A1 | New Pyridine Analogues III | P2RY12, P2RY1, P2RY11 | KDM4E 2658/4885HSD17B10 4115/4885L3MBTL1 4870/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | KDM4E 3901/4885HSD17B10 3604/4885L3MBTL1 4818/4885 |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | KDM4E 2864/4885HSD17B10 4541/4885L3MBTL1 4634/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | KDM4E 4200/4885HSD17B10 3908/4885L3MBTL1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.